Telix to Present at Jefferies London Healthcare Conference 2023
Telix today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference 2023.
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
Telix today announces it has signed an exclusive agreement with Denmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix’s investigational prostate cancer imaging agent, Illuccix® (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection) in the Nordic region.
Telix Completes Acquisition of Lightpoint Medical
Telix, today announces the completion of the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business (refer to announcement on 21 June 2023).
ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
Telix today announces positive preliminary results from the Phase I ProstACT SELECT study of its rADC therapy candidate TLX591 (Lutetium (177Lu) rosopatamab tetraxetan) for prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC).
Activities Report and Appendix 4C for the quarter ended 30 September 2023
Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023 (Q3 2023). All figures are in AUD$ unless otherwise stated and provided on an unaudited basis.
Telix Quarterly Results and Investor Call / Webcast Notification
Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 September 2023 on Wednesday 18 October 2023.
HRH Princess Astrid of Belgium visits Telix’s New European Manufacturing Facility in Brussels South
Telix has welcomed Her Royal Highness, Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company’s recently inaugurated production facility, in Brussels South (Seneffe) in the Wallonia region of Belgium.
Telix collaborates with Eckert & Ziegler and RefleXion Medical to Expand Treatment Options for Prostate Cancer Patients
Telix, Eckert & Ziegler, and RefleXion Medical today announced a comprehensive collaboration agreement to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically for radiolabeling, quality control and storage of molecular targeting radiotracers, referred to as BioGuides, that are used in biology-guided radiotherapy (BgRT) to direct the radiation beam to indicated solid tumor cancers.
Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
Telix today announces presentations featuring the Company’s theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 – 13 September 2023.